Spark Therapeutics Archives -

The technology behind virtual reality is rapidly advancing, allowing developers to create entire 3D hospitals for training purposes.

Could virtual reality become an essential tool for healthcare education?

https://pharmaphorum.com/digital/could-virtual-reality-become-an-essential-tool-for-healthcare-education/

News

Could Spark Therapeutics’ merger with Roche finally get the go-ahead?

Richard Staines M&A, Rare diseases, Roche, Spark Therapeutics 0 Comment

Spark Therapeutics’ merger with Roche has moved a step closer after the UK’s competition watchdog okayed the $4.8

Could Spark Therapeutics’ merger with Roche finally get the go-ahead?

https://pharmaphorum.com/news/could-spark-therapeutics-merger-with-roche-finally-get-the-go-ahead/

R&D/ R&D/ Views & Analysis/ Views and analysis

R&D Roundup: Pharma gets in on the biotech boom

George Underwood Alexion, Alnylam, Biotech, Cell Mogrify, Novartis, R&D, Roche, Spark Therapeutics, UK 0 Comment

Some good news for the UK industry in turbulent times is always welcome, and several announcement this month

R&D Roundup: Pharma gets in on the biotech boom

https://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-pharma-gets-in-on-the-biotech-boom/

News/ News/ R&D

Roche insists Spark deal is still on, despite lacklustre take-up

Phil Taylor gene therapy, Luxturna, Roche, Spark Therapeutics 0 Comment

Shareholders in Spark Therapeutics haven’t been queueing up to take advantage of Roche’s $114.50-per-share offer, forcing an extension

Roche insists Spark deal is still on, despite lacklustre take-up

https://pharmaphorum.com/news/roche-insists-spark-deal-still-on-despite-lacklustre-take-up/

News/ Top stories

Spark/Novartis eye gene therapy nears EU market – but at what price?

Richard Staines Novartis, ophthalmology, Rare diseases, Spark Therapeutics 0 Comment

Spark Therapeutics’ and Novartis Luxturna gene therapy for a rare inherited eye disease has been okayed by European

Spark/Novartis eye gene therapy nears EU market – but at what price?

https://pharmaphorum.com/news/spark-novartis-eye-gene-therapy-luxturna/

News/ News/ R&D

Spark shares tank after haemophilia gene therapy safety signal

Richard Staines gene therapy, Rare diseases, Spark Therapeutics 0 Comment

Biotech still pressing on with late stage trials

Spark shares tank after haemophilia gene therapy safety signal

https://pharmaphorum.com/news/spark-shares-tank-after-haemophilia-gene-therapy-safety-signal/

News/ R&D

Pfizer moves haemophilia gene therapy into phase 3

Piotr Wnuk haemophilia, haemophilia B, Pfizer, Spark Therapeutics 0 Comment

US pharma giant Pfizer and partner Spark Therapeutics has begun a phase 3 trial of a gene therapy

Pfizer moves haemophilia gene therapy into phase 3

https://pharmaphorum.com/r-d/pfizer-haemophilia-b-gene-therapy/

News/ Partner content/ Press releases

Your Latest Ophthalmology News for SMi’s Ophthalmic Drugs 2018

Pavan Solanki alimera, elasmogen, ophthalmic, ophthalmology, Spark Therapeutics 0 Comment

Ophthalmic Drugs Conference London

Your Latest Ophthalmology News for SMi’s Ophthalmic Drugs 2018

https://pharmaphorum.com/partner-content/your-latest-ophthalmology-news-for-smis-ophthalmic-drugs-2018/

News/ R&D/ Rare diseases

Priority review voucher prices fall again after Spark’s $110m sale

Richard Staines Jazz Pharmaceuticals, ophthalmology, Rare diseases, Spark Therapeutics 0 Comment

Voucher prices have fallen since their 2015 peak

Priority review voucher prices fall again after Spark’s $110m sale

https://pharmaphorum.com/news/spark-sells-priority-review-voucher-to-jazz/

Trending

Spark Therapeutics

Login